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Concerns have been raised regarding environmental manganese exposure since high exposures have been associated with
neurological disorders. The USA Environmental Protection Agency most recent human health risk assessment of inhaled
manganese conducted in 1993 identiﬁed speciﬁc areas of uncertainty regarding manganese pharmacokinetics. This led to the
development of a test rule under the USA Clean Air Act that required the generation of pharmacokinetic information on the
inorganic manganese combustion products of the organometallic fuel additive methylcyclopentadienyl manganese tricarbonyl
(MMT). The Alternative Tier 2 testing program for MMT, described in this paper, has yielded substantial pharmacokinetic data
andhasenabledthegenerationofphysiologicallybasedpharmacokinetic(PBPK)modelsformanganese.Thesemodelsarecapable
of predicting tissue manganese concentrations across a variety of dose routes, levels, and durations while accounting for factors
such as age, gender, and reproductive status, enabling the consideration of tissue dosimetry in future risk assessments.
1.Introduction
Methylcyclopentadienyl manganese tricarbonyl (MMT,a
registered trademark of Afton Chemical Corporation) is
an organometallic fuel additive that was developed by the
Ethyl Corporation in the 1950s. MMT is currently marketed
globally by Afton Chemical Corporation among others.
MMT has been used in a variety of fuels, including leaded
and unleaded gasoline, diesel and turbine fuel, and fuel oil
to raise octane and improve combustion [1]. Manganese
concentrations in unleaded gasoline typically range from 5
to 20ppm when MMT is used. In the United States, MMT
is approved for use up to 8.3ppm in conventional unleaded
gasoline.
As a fuel additive, MMT falls under the regula-
tory domain of the United States Environmental Protec-
tion Agency (USEPA), and MMT manufacturers and/or
importersaresubjecttorelevantprovisionsoftheUSAClean
Air Act (CAA). This paper provides an overview of the novel
CAA Alternative Tier 2 test program for MMT designed to
collect critical manganese pharmacokinetic data in animals
(alltestreportsandcorrespondencerelatedtotheAlternative
Tier 2 Testing for MMT can be found in the Federal Docket
Management System (FDMS) at http://www.regulations.gov
identiﬁed by docket number EPA-HQ-OAR-2004-0074.).
Follow-up eﬀorts led to the development of a series of
physiologically based pharmacokinetic (PBPK) models for
manganese. This paper will brieﬂy examine the toxicology
of manganese, the regulatory history of MMT, the design
and conduct of the Alternative Tier 2 program for MMT,
key research ﬁndings derived from the health eﬀects research
program, and critical lessons learned that can be applied to
other chemicals. The second paper in this two-part series [2]
describes the PBPK models in greater detail and provides
a framework for their application to the risk assessment of
manganese.2 Journal of Toxicology
2.ManganeseToxicology: PublicHealth
Concerns about MMT
Manganese is an essential trace metal that is required
for normal amino acid, lipid, protein, and carbohydrate
metabolism. Under certain high-dose exposure conditions
or disease states (e.g., hepatobiliary dysfunction), however,
manganese can induce adverse neurological, reproductive,
and respiratory eﬀects in humans [3]. Manganese toxicity
is dependent on the dose to target tissue and develops
after inhalation, oral, and parenteral exposure; however,
this paper will focus predominantly on inhalation. Atmo-
spheric sources of manganese include manmade and natural
sources including wind erosion of dusts and soils. Industries
associated with manganese emissions include ferroalloy
production, iron and steel foundries, and power plant and
coke oven combustion emissions. Ambient (background)
levels of manganese in rural and urban air range from 0.005
to 0.07µgMn/m 3 [4].
Neurological eﬀects occur at lower dose levels than other
adverse eﬀects, so consideration of these eﬀects drives the
human health risk assessment of inhaled manganese [4–
6]. The earliest manifestations of manganese neurotoxicity
(manganism) include fatigue, headache, muscle cramps, loss
of appetite, apathy, insomnia, and diminished libido. As
manganese exposure continues and the disease progresses,
patients may develop dystonia, bradykinesia, rigidity, gait
disorders, postural instability, micrographia, and muscle
tremors (for review see [7]). These signs are associated
with primary involvement of the globus pallidus. Individuals
with chronic manganese neurotoxicity resemble patients
with Parkinson’s disease; however, these syndromes can be
distinguished both clinically and with neuroimaging studies
[7]. Although these syndromes are clinically distinct, some
studies suggest that manganese overexposure may pose a risk
factor for Parkinson’s disease [7, 8].
A variety of inhalation exposure scenarios exist for
manganese from occupational settings with mid- to high-
doseexposurestomuchlowerexposuresfoundinthegeneral
environment. Forms of manganese include but are not lim-
ited to manganese dioxide (MnO2) and other oxides, man-
ganese sulfate (MnSO4), manganese phosphates (MnPO4),
andorganometallicmanganesecompounds.Absentunderly-
ing hepatobiliary disease, frank manganese neurotoxicity has
been observed in workers that have been chronically exposed
to dusts or fumes that contain high levels (>1mgMn/m 3)
of manganese [4]. More subtle neurobehavioral eﬀects
have been reported in welders and other workers at lower
(∼0.2mgMn/m3) exposure concentrations [9]. One of the
more inﬂuential occupational studies was performed by
Roels and coworkers [10]. This cross-sectional study of male
workers was used by the USEPA as their critical study for
deriving their chronic inhalation reference concentration for
manganese (RfC) of 0.05µg/m3 that was last updated in
1993 [6]. According to USEPA, an RfC is an estimate (with
uncertainty spanning perhaps an order of magnitude) of a
continuous inhalation exposure to the human population
(including sensitive subgroups) that is likely to be without an
appreciable risk of deleterious eﬀects during a lifetime. Roels
et al. [10] assessed employees from a Belgian alkaline battery
production plant and controls from a polymer processing
plant. Personal air samplers in the battery plant indicated an
8hr time weighted average (TWA) exposure of 0.215mg/m3
for respirable manganese. An average cumulative exposure
of 1.2mg/m3·years of respirable manganese was associated
with decrements in some neurofunctional performances
(e.g., mean reaction times, eye-hand coordination and
muscles tremor scores) between the exposed group and
the control group. Health Canada current risk assessment
relied on a study of Italian ferroalloy workers performed
by Lucchini and coworkers [11] for the derivation of their
RfC for manganese [5]. Lucchini examined several cohorts
of workers (furnace, casting, and welding job functions)
between 1981 and 1997. Manganese exposures for all classes
of workers dropped appreciably during this time. For exam-
ple, the geometric mean manganese concentrations (in total
dust) went from 167 to 54.7µg/m3 in the maintenance area
wherewelding wasperformed.Anexposure concentrationof
approximately 71µgMn/m 3 was derived from an estimated
cumulative exposure index. Lucchini reported an associa-
tion between occupational manganese exposure and some
neurological eﬀects including higher symptom reporting,
increased tremor frequency, altered motor function, and
impaired memory. Bailey and colleagues [12] published an
alternative RfC value of 2–7µgM n / m 3 that was based upon
their use of epidemiological studies published after 1992.
The American Conference of Industrial Hygienists (ACGIH)
threshold limit value (TLV) for elemental manganese and
related inorganic compounds is 0.2mgMn/m3 [13]. This
standard is set as a time-weighted average for an 8hr shift
5 days per week designed to protect workers in occupational
settings.
Ambient manganese exposure data are needed to assess
the potential public health impacts of MMT in fuel. Several
of the most signiﬁcant studies were performed in Canadian
cities when MMT was widely used in the local fuel supply.
For example, an extremely large eﬀort using probabilistic
sampling techniques measured manganese exposure levels
in Toronto residents when all fuel contained MMT [14].
The results of this study and related analyses of data
from personal samplers [15, 16] suggest that the median
annualized nonoccupational exposure concentration was
0.008µg/m3 with the highest long-term exposures at or
near 0.022µg/m3. as a respirable fraction (PM2.5). Roadway
measurement of soil manganese concentrations did not
revealameasurableincreaseinmanganeselevelsalongurban
Toronto highways [17]. Studies from Australia have shed
additional light on the impact of MMT on atmospheric
manganese concentrations [18, 19]. Gulson and coworkers
reported no signiﬁcant changes in environmental samples or
blood manganese concentrations in children following the
introduction of MMT in Sydney.
Concerns regarding the use of MMT as a gasoline fuel
additive have also been inﬂuenced by the USA experience
of tetraethyl lead in gasoline. Concerns about automotive
emissions of lead prompted the USEPA in 1973 to phase
out the use of lead in gasoline [20]. The experience with
tetraethyl lead created an environment of distrust betweenJournal of Toxicology 3
public health oﬃcials, environmental legislators, advocacy
groups, and fuel manufacturers. USEPA health eﬀects testing
program for MMT emerged from this challenging climate.
3. Overview of the Regulatory History of MMT
Manganese is listed as an air toxic by the USEPA. When the
USEPA ordered the phasing out of leaded gasoline, MMT
andotheralternativeoctaneenhancerswereusedinunleaded
gasoline. In 1977, a Congressional amendment to the CAA
bannedtheuseofallfueladditivesnot“substantiallysimilar”
to gasoline, including MMT, unless the USEPA granted
aw a i v e r[ 21]. The prohibition on the use of MMT in
gasoline was largely based on concerns that MMT use
could aﬀect the ﬁrst generation of automotive emissions-
control systems. Ethyl Corporation ﬁrst applied for this
waiver in 1978. This and several subsequent waiver petitions
submitted by Ethyl Corporation were denied because of
USEPA concerns regarding potential increases in exhaust
hydrocarbon emissions resulting from MMT use [21].
As part of a later waiver application for MMT, the
USEPA conducted a risk assessment of exposure to inhaled
manganese in 1993, with the publication of an inhalation
RfC of 0.05µg/m3 [6]. The USEPA used standard RfC devel-
opment methodologies for a noncancer endpoint and based
the RfC on the Roels et al. study [10] that evaluated neu-
robehavioral and motor movement impairments observed
in workers exposed to manganese dioxide (MnO2). The
exposure concentration reported by Roels was considered
by the USEPA to be a lowest-observable-adverse-eﬀect level
(LOAEL). The LOAEL value was adjusted for continuous
exposure durations, and several uncertainty factors were
applied. These uncertainty factors included use of a LOAEL
instead of a no-observable-adverse-eﬀect level (NOAEL),
extrapolation from subchronic to chronic, protection of
potential sensitive members of the human population, and
a factor reﬂecting other uncertainties in the database, such as
less-than chronic periods of exposure, inadequate informa-
tion regarding developmental and reproductive toxicity, and
uncertaintyaboutthetoxicityofvariousformsofmanganese
[22]. Although the nutritional essentiality of manganese in
the diet was discussed in the documentation of the RfC, it
played no practical role in the calculation of an RfC [21].
The USEPA also published a risk characterization that
included exposure and dose-response assessments for MMT
in gasoline [23, 24]. After completing this evaluation,
EPA determined that use of MMT would not “cause or
contribute”tothefailureofvehicleemissioncontrolsystems.
EPA was unable to determine, however, whether a risk to
the public health occurred from use in gasoline [25]. The
agency stated “[a]lthough it is not possible based on the
present information to conclude whether speciﬁc adverse
health eﬀects will be associated with manganese exposures
in the vicinity of or exceeding the (estimated safe level over
a lifetime of exposure), neither is it possible to conclude
that adverse health eﬀects will not be associated with such
exposures...Giventheinformationthatisavailableatpresent
and the uncertainties discussed here, a reasonable basis exists
for concern regarding potential public health risks, especially
for sensitive subpopulations, if MMT were to be widely used
in unleaded gasoline [25].” The USEPA also concluded that
long-term animal testing and exposure research were needed
to more accurately deﬁne the risk. Coincidental to these
activities, in July 1994, the USEPA Administrator denied
EthylCorporationnewestwaiverpetitionspeciﬁcallybecause
of concerns about potential risks to public health [24]a n d
refused to register MMT for use in the USA In 1995, the
Ethyl Corporation successfully challenged the denial of its
petition based on public health concerns (Ethyl Corporation
v. Browner, 51 F.3d 1053 (D.C. Cir. 1995)), as well as USEPA
decision not to register MMT (Ethyl Corporation v. Browner,
67F.3d941(D.C.Cir.1995)).Asaresult,theUSEPAformally
approved the use of MMT in conventional unleaded gasoline
and registered it as a fuel additive under the CAA, allowing
for its domestic sale.
Provisions of the CAA provide the USEPA with the
authority to require testing of fuels and fuel additives used
in motor vehicles, including MMT, to help ﬁll data gaps and
provide information that potentially would result in a more
deﬁnitive risk evaluation. These health testing requirements
are addressed in Sections 211(b)(2) and 211(e) of the CAA.
Section 211(b)(2) states “For the purpose of registration of
fuels and fuel additives, the Administrator shall, on a regular
basis, require the manufacturer of any fuel or fuel additive”
to conduct“Tier 2” tests to determine potential public health
and environmental eﬀects of the fuel or additive (including
carcinogenic, teratogenic, or mutagenic eﬀects). These stud-
ies would be conducted using test procedures and protocols
established by the USEPA. Moreover, the CAA also provides
USEPA with the discretion to modify the standard Tier 2
health eﬀects testing requirements for a fuel or fuel additive
by substituting, adding, or deleting testing requirements or
changing the underlying vehicle/engine speciﬁcations (40
CFR 79.58(c)). Health eﬀects testing for MMT fell under this
so-called “Alternative Tier 2” requirement, as the concern
and subsequent testing was focused around the inorganic
exhaust products of MMT and not MMT itself.
4. Establishment of the AlternativeTier 2
Testing Program for MMT
In 2001, the Ethyl Corporation was notiﬁed by the USEPA
of the Alternative Tier 2 provisions for MMT which fell
within two general categories: pharmacokinetic testing of
manganese compounds and characterization of manganese
emissions from vehicles utilizing fuels containing MMT. A
central objective of the MMT Alternative Tier 2 program was
to generate data to support development of physiologically
based pharmacokinetic (PBPK) models for manganese. As
a result, PBPK model development became the subject of
a series of studies funded by Afton Chemical Corp. and
handled in a way similar to other facets of the Alternative
Tier 2 program.
Multiple pharmacokinetic studies were performed in
response to the USEPA mandate (Table 1). Studies that were
required by the USEPA were performed in accordance with4 Journal of Toxicology
Table 1: Overview of the pharmacokinetic studies conducted in response to the Alternative Tier 2 test program for MMT. The following
forms of manganese (Mn) were used in these studies: Mn tetroxide, Mn sulfate, and Mn phosphate. Some studies also involved intravenous
administration of radiolabeled Mn chloride (54MnCl2) to assess whole-body (WB) clearance.
Pharmacokinetic endpoint
of interest
Regulatory
Status
Animal
Species
Manganese species and exposure
conditions
Primary
publication(s)
Particle solubility and
dissolution kinetics Voluntary Rat
Phosphate, sulfate, and
tetraoxide—intratracheal instillation
0, 0.04, 0.08, or 0.16µgMn/g
Rats killed at 0, 1, 3, or 14 d
[42]
Exposure-response and WB
clearance Voluntary Rat
Phosphate inhalation
6h/d for either 5d/wk or 7d/wk at 0,
0.03, 0.3, or 3mgMn/m3 f o ru pt o1 4d
[43]
Particle solubility and WB
clearance Voluntary Rat
Sulfate and tetroxide inhalation
6h/d for 7 d/wk at 0, 0.03, 0.3, or
3mgMn/m3 for 14d
[44]
Diet-inhalation interaction
and WB clearance Voluntary Rat
Sulfate or tetroxide inhalation
6h/d for 7d/wk at 0, 0.03, or
0.3mgMn/m3 for 14d
Low (2ppm), suﬃcient (10ppm), or high
(100ppm) Mn diets
[45, 46]
Olfactory transport of Mn Voluntary Rat
Chloride and phosphate inhalation
∼0.5mgMn/m3 for 90min
Occluded nostril model
[47, 48]
Individual susceptibility
WB clearance
Nasal pathology
Required Rat
Inhalation
E x p o s e d6h / df o r5d / w kt os u l f a t ea t
0.01, 0.1, or 0.5mgMn/m3 or phosphate
at 0.1mgMn/m3 f o ru pt o9 0d
Adult male, adult female, and senescent
male
[49, 50]
Individual susceptibility Required Rat
Sulfate inhalation
Exposed 6h/d for 7d/wk at 0, 0.05, 0.5,
or 1mgMn/m3 throughout the majority
of pregnancy or lactation.
[41, 51]
Species diﬀerences
Brain imaging
Respiratory tract pathology
and neurochemistry
Required Rhesus
monkey
Sulfate inhalation
Exposed 6h/d for 5d/wk at 0, 0.06, 0.3,
or 1.5mgMn/m3 for up to 90d.
[34–38]
the USEPA Good Laboratory Practice (GLP) Standards for
Inhalation Exposure Health Eﬀects Testing (40 CFR Part
79.60). All studies were performed at The Hamner Institutes
for Health Sciences (Hamner) (formerly the Chemical
Industry Institute of Toxicology (CIIT)). All required study
protocols, protocol amendments, and draft ﬁnal reports
underwent independent scientiﬁc review by project speciﬁc
“technical advisory panels” (TAPs) composed of individuals
with expertise in inhalation toxicology, pharmacokinetics,
andneurotoxicology(Figure 1).MembersoftheTAPs,which
changed for the diﬀerent facets of the test program, were
chosen by the study sponsor with input from the testing
laboratory and approved by the USEPA. All study results
underwent additional independent peer review during sub-
sequent publication of the work in scientiﬁc journals.
Several critical decisions were reached early in the MMT
test program. These concerned the form of manganese
to be examined, animal species used, and endpoints of
interest. The main focus of the test program was to evaluate
combustion products of MMT. This decision was inﬂuenced
in part by the observation that MMT undergoes rapid
photolysiswhenexposedtolight,formingmethylcyclopenta-
diene, cyclopentadiene, carbon monoxide, and a manganese
carbonyl that is readily oxidized to trimanganese tetroxide
[26]. One early dilemma facing study toxicologists was
determination of these combustion products. Early studies
performed by Ter Haar and coworkers [27] showed that
the primary combustion product from MMT was Mn3O4.
This study used fuel spiked with large concentrations of
MMT, an automobile without a catalytic converter, and X-
ray diﬀraction methods for chemical speciation, resulting in
an artifactual apparent enrichment of Mn3O4 in the exhaust.
Zayed et al. [28], using scanning electron microscopy
coupled with energy dispersive X-ray spectrometry, also
suggested that the chemical form of emitted manganese
was as an oxide but could not rule out sulfates and other
manganese species. Other studies, using lower treat rates
representative of actual use patterns and more advanced
analytical methods, including X-ray absorption near-edge
structure (XANES) spectra and K-edge X-ray absorptionJournal of Toxicology 5
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Figure 1: Schematic overview of steps used to develop and review study protocols and produce ﬁnal reports. Independent peer review
was carried out by the appropriate TAP. Completed ﬁnal reports for all of the manganese studies can be found in the Federal Docket
Management System (FDMS) at http://www.regulations.gov identiﬁed by docket number EPA-HQ-OAR-2004-0074. EPA: Environmental
P r o t e c t i o nA g e n c y ;O R D :E P AO ﬃce of Research and Development.
ﬁne structure (XAFS) spectroscopy, showed the presence of
three major manganese-containing components in tailpipe
emissions: a divalent manganese phosphate, sulfate, and
oxides (most likely as Mn3O4)[ 29–31]. The percentage of
each component varied somewhat depending on the driving
cycle and vehicle but remained relatively constant with the
sulfate and the phosphate forms being the major (∼80%)
components [1].
The USEPA subsequently agreed to the use of com-
mercially available manganese phosphate (as hureaulite),
MnSO4,a n dM n 3O4 for the inhalation studies rather than
rely on the use of a dynamometer system that used MMT in
thefuelsourcetogenerateexhaustparticulates.Thisdecision
also allowed the Hamner research team to achieve the high
exposure concentrations (mg/m3) required to conduct the
study. Such high concentrations were necessary to ensure
tissue accumulation so the data could be used to inform
thesubsequentPBPKmodels.Similaraerosolconcentrations
andparticlesizeswereusedintheHamnerinhalationstudies
to facilitate direct comparison of tissue manganese burdens
among these experiments. Early studies used all three forms
of manganese while later experiments relied upon the form
of manganese (MnSO4) that produced the greatest increase
in brain manganese concentrations, representing a “worse-
case scenario” with regards to potential brain delivery.
Another unique feature of the MMT alternative Tier 2
test program was the use of rhesus monkeys for certain stud-
ies.Asubstantialliteraturebasedescribingspeciesdiﬀerences
in neurological responses following high-dose manganese
exposure existed at the time the Alternative Tier 2 program
was launched. Unlike rats, manganese-exposed monkeys
develop distribution patterns for this metal within the brain
that mimic those seen in heavily exposed people and develop
similar neuropathology and behavioral responses [32–34].
Despite these pharmacodynamic diﬀerences in response
between rats and humans, pharmacokinetic data obtained
from rats remained valuable because rats and primates show
similar overall pharmacokinetic responses to manganese
exposure, including the induction of homeostatic control
mechanisms. The rat data provided critical insights into the
dose-response relationship for inhaled manganese, especially
during diﬀerent life stages.
Once the decision to use rhesus monkeys was reached,
there was a concerted eﬀort to maximize the data that could
be obtained from this study. Study endpoints included tissue
manganese concentrations following MnSO4 exposure [35],
brain magnetic resonance imaging (MRI) studies [36], respi-
ratory tract pathology [37], catecholamine neurochemistry
[38], biomarkers of neurotoxicity and oxidative stress [39],
and metabolomic biomarkers of exposure [40]. The USEPA
waived the GLP requirements for certain study endpoints,
including the MRI study, neurochemistry measurements,
and the assessment of biomarker endpoints.
Another challenge that faced the research team was
conduct of the required gestational and lactational inhala-
tional studies. These studies required the coexposure of
lactating rat dams and their pups. Inhalation developmental
neurotoxicity and pharmacokinetic studies generally rely on
maternal separation during exposure, resulting in pup stress
that may alter development, thereby confounding study
results. To overcome this potential confounding variable,
Vitarella and coworkers [41] developed a unique single-
animal exposure cylinder designed to house a rat dam
and her litter. These investigators ﬁrst tested concentrations
of manganese phosphate within the exposure cylinder to
verify that particle concentrations within this system were
equivalent to those achieved within a stainless steel 1-m3
inhalation chamber. Once developed, this system was then
used to support the rat lactational exposure study required
by the USEPA [42].
5.Key Research Findings
Anumberofsigniﬁcantdiscoveriesemergedfromthistesting
program(Table 2).Whilethesestudiesaredescribedindetail6 Journal of Toxicology
Table 2: Notable scientiﬁc contributions derived from the MMT Alternative Tier 2 test program.
Pharmacokinetic endpoint Key Finding(s)
Chemical form of manganese Lung uptake and brain (tissue) delivery is highly inﬂuenced by solubility (sulfate   phosphate
> tetroxide)
Dose and duration dependences
Manganese uptake and elimination rates depend on exposure dose and exposure duration
Delivery to the brain and development of pseudosteady manganese concentrations develop
rapidly
Biliary excretion shows similar time and concentration dependencies.
Homeostatic control Manganese concentration in brain remains controlled at low levels of exposure and
accumulates at air concentrations >10–50µg/m3
Dose metrics Dose rate rather than cumulative dose appears to be the appropriate dose metric at low levels
of exposure
Route of exposure The observed pharmacokinetic diﬀerences between dietary and inhaled manganese can be
attributed to rates of uptake and elimination required to achieve the same target tissue doses
Olfactory transport Inhaled manganese is taken up by the nasal olfactory epithelium and transported directly via
the olfactory nerve to the olfactory bulb
Species diﬀerences
Despite speciﬁc pharmacokinetic diﬀerences between rats and nonhuman primates, similar
overall pharmacokinetic responses to and homeostatic controls of manganese were observed
across species
in their individual publications, several signiﬁcant ﬁndings
are summarized here.
Solubility. The Hamner particle solubility studies showed
that hureaulite and Mn3O4 are relatively insoluble in simu-
lated lung lining ﬂuids, while MnSO4 is considerably more
soluble in biological ﬂuids [52]. These studies also showed
that soluble manganese forms like the sulfate are more
rapidly cleared from the rat lung and delivered to the rat
brain following inhalation than are insoluble manganese
oxide and phosphate particles.
Direct Olfactory to Deep Brain Transport. One project goal
was to determine whether inhaled manganese could be
transported to the brain directly via the olfactory nerve.
Interest in this topic was sparked by the knowledge that the
olfactory system forms a direct interface between the air and
thebrain.TheHamnerconductedstudiesinratsusingshort-
term (90min) inhalation exposure to radiolabeled (54Mn)
aerosols in rats with one occluded nostril, thus restricting
olfactory transport of manganese to only one side of the rat
brain. These novel studies dramatically demonstrated that
the olfactory route contributes the vast majority (>90%) of
the 54Mn found in the olfactory pathway of the rat brain
up to 8 days following acute inhalation exposure. To our
knowledge, this was the ﬁrst study to demonstrate that
an inhaled metal could be delivered to the olfactory brain
regions directly via the olfactory nerve. Although olfactory
transport rapidly delivers manganese to brain structures
in the olfactory pathway, it appears to be relatively slow
(and ineﬃcient) in delivering inhaled manganese to the rat
striatum and other more distant brain structures [53].
Addition of Inhaled Manganese to Existing Oral Exposures.
Individuals with either deﬁcient or excessive manganese
tissue burdens have been postulated to be at increased risk
for manganese toxicity following inhalation exposure [45].
Two related 14-day inhalation studies conducted by the
Hamner demonstrated that manganese body burden does
not inﬂuence brain manganese concentrations following
inhalation [44, 54]. These studies placed postnatal day
(PND) 10 rats on specially formulated diets that contained 2,
10,or100ppmmanganese.Thelowestandhighestdietswere
chosen in order to provide the animals with a marginally
deﬁcient or high-normal level of manganese. The 10ppm
manganese diet used in the studies met rodent dietary
guidelines. Once tissue manganese concentrations stabilized
(i.e., after 2 months on the special diets), rats were exposed
bywhole-bodyinhalationfor6hr/dayon14consecutivedays
to MnSO4 or Mn3O4 at concentrations equivalent to 0, 0.03,
or 0.3mgMn/m3. Feeding the 2ppm manganese diet was
associated with a number of eﬀects, including reduced body
weight gain, decreased liver manganese concentrations, and
reduced whole-body manganese clearance rates. Although
rats kept on this diet and then exposed to 0.3mgMn/m3
developed increased manganese concentrations in some
tissues, the studies did not demonstrate any statistically sig-
niﬁcant diet and inhalation interactions on brain manganese
concentrations.
Neonatal Exposures. Concerns have been raised regarding
increased risk of neonates for manganese-induced neuro-
toxicity [32]. The increased sensitivity of neonatal animals
to manganese appears to be due in part to their ability to
develop higher brain manganese levels than adults when
facedwithequivalentorlessermanganeseexposuresbyhigh-
dose oral gavage [51]. Factors inﬂuencing this increased
susceptibility of neonatal animals may include enhanced
manganese absorption from the gastrointestinal tract, an
incompletely formed blood-brain barrier, and a greatly
reduced basal biliary manganese excretory rate until wean-
ing. However, information was more limited regarding the
potential risks in neonates exposed to airborne manganese.
To further assess this concern, the Hamner exposed ratJournal of Toxicology 7
dams and their oﬀspring to air or MnSO4 (0.05, 0.5, or
1mgMn/m 3) for 6hr/day, 7 days/week starting 28 days prior
to breeding and fromPND 1 through 18. The experimentally
determined manganese concentration in neonatal striatum
and the model-predicted AUC for this brain region did
not imply signiﬁcantly higher exposures in the pups when
compared to those in adults up to the inhaled dose of
1mg/m 3 [55, 56]. Despite the virtual absence of basal biliary
excretion in neonatal rats, they appear to induce their biliary
excretion when challenged with excess manganese through
the oral route [57]. This inducible excretion in neonates
was shown to be applicable to inhaled manganese as well
to a level comparable to adults [56]. Because neonates have
an increased requirement for manganese for optimal brain
development, further elaboration of the dose-response rela-
tionship between brain manganese levels and neurotoxicity
may further elucidate the potential vulnerability of neonatal
brain to manganese.
Studies in Rhesus Monkeys. The Hamner inhalation study
that exposed juvenile rhesus monkeys to MnSO4 is amongst
the most critical completed to date with manganese. In this
study, one group of monkeys was exposed to either air or
MnSO4 (0.06, 0.3, or 1.5mgMn/m3)f o r6 5e x p o s u r ed a y s
(6hr/day, 5 days/week) before tissue analysis. Additional
m o n k e y sw e r ee x p o s e dt oM n S O 4 at 1.5mgMn/m3 for 15
or 33 exposure days and evaluated immediately thereafter or
for 65 exposure days followed by a 45- or 90-day delay before
evaluation. Monkeys exposed to MnSO4 at ≥0.06mgMn/m3
developedincreasedmanganeseconcentrationsintheglobus
pallidus, putamen, olfactory epithelium, olfactory bulb,
and cerebellum. Absolute manganese concentrations in
the MnSO4-exposed monkeys demonstrated a decreasing
peripheral-central concentration gradient within the olfac-
tory system (i.e., olfactory epithelium   olfactory bulb >
olfactory tract > olfactory cortex). These data are consis-
tent with direct olfactory transport of inhaled manganese.
Increasedpallidalmanganeseconcentrationswereevidentby
brainMRIandfurtherconﬁrmedbyatomicabsorptionspec-
trometry analysis of the tissues [36]. MRI changes seen in
this monkey study were similar to those reported in welders
that have had high manganese exposure and subsequently
developed bilateral hyperintensity on T1-weighted images
in the globus pallidus and other brain regions [7]. Signal
hyperintensities could not be visualized by MRI between the
olfactory bulb and more distal sites, suggesting that direct
translocation of manganese from the olfactory bulb to the
globus pallidus did not occur in the manganese-exposed
monkeys. Metabolomic analysis of serum and chemical
analysis of brain tissues from the MnSO4-exposed monkeys
revealed changes indicative of oxidative stress at higher
exposure concentrations [39, 40]. Dorman and coworkers
[37] also reported that exposure of monkeys to MnSO4 at
1.5mgMn/m3 for ≥15 exposure days resulted in increased
lungmanganeseconcentrations,mildsubacutebronchiolitis,
alveolar duct inﬂammation, and proliferation of bronchus-
associated lymphoid tissue. Bronchiolitis and alveolar duct
i n ﬂ a m m a t o r yc h a n g e sw e r ea b s e n t4 5d a y sa f t e re x p o s u r e ,
suggesting that these lesions are reversible upon cessation of
subchronic high-dose manganese exposure.
6.Lessons Learned
The work described herein represents the most extensive
set of pharmacokinetic studies performed to date under the
USEPA Alternative Tier 2 requirements. The pharmacoki-
netic data that was collected through this testing program
has dramatically improved our understanding of the health
risks posed by manganese. These studies have led to an
improved understanding of the exposure conditions that
lead to increased concentrations of the metal within the
adult and developing brain and other tissues. This work
has also led to the development of predictive, PBPK models
for inhaled manganese that relate lung, brain, and other
tissue manganese concentrations to exposure concentrations
[2]. These PBPK models should lead to the development of
human health risk assessments for inhaled manganese that
will consider both its essentiality and neurotoxicity.
This testing program also represents an example of
productive industry/government cooperation despite the
challenging regulatory climate under which it commenced
[22]. Evidence of cooperation was manifested by the
sponsor’s willingness to conduct additional studies that
were outside of the scope of the required testing pro-
gram. Some examples included work to evaluate olfactory
transport of manganese following inhalation, short-term (2
weeks) pharmacokinetic studies, and experiments designed
to examine the elimination kinetics of inhaled manganese
(see Table 1). Many of these studies were needed to develop
the framework for subsequent development of the PBPK
models. In addition, the sponsor also voluntarily developed
the human PBPK models, as only the animal models were
required by USEPA. All parties involved in this program
shared a common desire to develop the most robust set of
experiments possible. Figure 1 shows the extensive review
and oversight by EPA and others that contributed to the
development of robust experimental protocols. In addition,
all parties involved recognized the value of the development
and use of novel technologies (e.g., inhalation exposure
systems for lactating rats) and incorporation of a wide array
of endpoints, including MRI. There was also great value
in conducting the work at a multidisciplinary indepen-
dent research institute that could help facilitate discussions
between the USEPA and the research sponsor. Incorporation
of additional manganese TAPs composed of external experts
also built on the Hamner’s rich history of independent
external peer review of their research programs. This testing
program also beneﬁted from multiple postdoctoral fellows
and undergraduate researchers; thus, this program also
played a key role in training new scientists.
Finally, the MMT testing program is aligned with the
National Research Council vision described in their report
entitled “Toxicity Testing in the 21st Century: A Vision
and a Strategy” [58]. The three main components of the
NRC vision for the future of toxicity testing are chemical
characterization, toxicity testing, and dose-response and8 Journal of Toxicology
extrapolation modeling. The NCR vision also describes a
paradigm shift away from a focus on identifying adverse
eﬀects observed in experimental animals at high doses
toward identifying and avoiding biologically signiﬁcant per-
turbations of key toxicity pathways [59]. The identiﬁcation
of transition points between normal function and exposures
that lead to accumulation and eﬀects of an agent, as well
as a consideration of the adaptive changes that respond to
initial perturbations and function to maintain homeostasis,
is a key to the NRC vision (see [58, Figure 2.2]). In our
opinion, signiﬁcant changes in tissue manganese concentra-
tions represent a critical early step in the development of
manganese neurotoxicity. Importantly, this work has iden-
tiﬁed a dose-dependent transition in manganese kinetics,
which is a point where there is a change in the relationship
of tissue accumulation as a function of dose [60, 61]. The
pharmacokinetic data and PBPK modeling have shown that
background tissue manganese levels are well maintained at
low to moderate exposure levels, due to the existence of
homeostatic control mechanisms, such as increased biliary
manganese excretion, that serve to regulate tissue levels.
Only once those mechanisms are overwhelmed do tissue
levels start to increase signiﬁcantly. Due to the existence
of this dose-dependent transition, only roughly one order
of magnitude separates the point of departures on which
previous manganese risk assessments are based and a level
of exposure at which no signiﬁcant changes in Mn tissue
concentrationispredictedtooccurintargettissues.Thismay
indicatethatlargeuncertaintyfactorsarenotnecessarywhen
extrapolating high-dose occupational exposure levels to low
e n v i r o n m e n t a le x p o s u r el e v e l sf o rt h eg e n e r a lp o p u l a t i o nf o r
an essential element such as Mn. The human PBPK models
for Mn that emerged from this program can be used to
further analyze the relationship between exposure and target
tissue concentration and provide a consistent dose-response
relationshipfortheeﬀectsofMnregardlessofexposureroute
and duration [43]. The models can be used to extrapolate to
lower exposures to determine a concentration at which no
signiﬁcant eﬀect on brain concentrations would be expected
compared to normal variation. The human PBPK model
can consider all life stages (fetuses, neonates, adults, and old
a g e ) ,b o t hg e n d e r s ,p r e g n a n c y ,a n df o r mo fM n .T h i sm o d e l
will be a critical tool for the quantitative risk assessment
of environmental and occupational exposures to Mn. The
model and these applications are discussed in more detail in
P a r t2o ft h i ss e r i e s[ 2].
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